News Mylan to develop Botox biosimilar with Revance Mylan takes aim at Allergan's off-patent blockbuster
News Samsung Bioepis Herceptin biosimilar approved in EU Mylan and Biocon resolve biosimilar manufacturing issues
News FDA rejects Mylan and Biocon biosimilar, citing manufacturin... Neulasta biosimilar hits trouble with regulators because of manufacturing issues
News Copaxone first on FDA's list for faster complex generic appr... Teva will attempt to block generic launch in courts
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.